FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Oxylanthanum Carbonate Complete Response Letter

[ Price : $8.95]

FDA issues a complete response letter to Unicycive Therapeutics for its hyperphosphatemia drug oxylanthanum carbonate that cites i...

FDA Accelerated Approval for Dizal Zegfrovy

[ Price : $8.95]

FDA gives accelerated approval to Dizals lung cancer drug Zegfrovy, along with a companion diagnostic device.

Staska Multiple Outsourcing Facility Violations

[ Price : $8.95]

FDA warns Staska Pharmaceuticals, a Bennett, NE, outsourcing facility, about its multiple failures to meet requirements for such f...

Abiomed Pump Controller Needs Update: FDA

[ Price : $8.95]

FDA issues an Early Alert for an Abiomed Automated Impella Controller issue that has resulted in three deaths.

Delayed Hereditary Angioedema Drug Wins Approval

[ Price : $8.95]

After delaying a review action last month, FDA now approves a KalVista Pharmaceuticals NDA for Ekterly (sebetralstat) for treating...

FDA Priority Review for Hunter Syndrome Therapy

[ Price : $8.95]

FDA accepts for priority review a Denali Therapeutics BLA for tividenofusp alfa for treating Hunter syndrome.

FDA Inspectors Say Conditions Still Hard

[ Price : $8.95]

A ProPublica investigative report says FDA inspectors continue to have issues arising from the dismissal of many of their support ...

FDA WEBVIEW CLOSED JULY 4TH WEEK

[ Price : $8.95]

In annual observance of the Fourth of July (Independence Day) holiday in the U.S., FDA Webview closes its news operations until Mo...

Report Highlights Study Demographic Representation

[ Price : $8.95]

A new FDA report examines the demographic representation of clinical trials supporting the approval of 50 novel drug therapies las...

REMS Requirements Ended for CAR T Cell Therapies

[ Price : $8.95]

FDA removes risk evaluation and mitigation strategies requirements for all currently approved CAR T cell therapies, saying the pro...